- PR Newswire•8 days ago
SAN DIEGO, Oct. 17, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, today announced that its Chief Executive Officer, Bill Welch, ...
- Zacks•20 days ago
Trovagene Inc. (TROV) has been recently selected as the liquid biopsy provider for a study named Precision Promise, a large-scale precision medical trial to treat pancreatic cancer patients.
- PR Newswire•21 days agoTrovagene's Liquid Biopsy in Groundbreaking National Initiative to Transform Outcomes for Pancreatic Cancer Patients
SAN DIEGO, Oct. 4, 2016 /PRNewswire/ -- Trovagene, Inc. (TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced today that it has been selected by the Pancreatic Cancer Action Network as the liquid biopsy provider to participate in Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. The Pancreatic Cancer Action Network is the leading non-profit organization committed to increasing survival for people diagnosed with pancreatic cancer, and is making an initial investment of $35 million to accelerate the clinical trial process to bring promising therapies to patients faster. As a founding member of the initial Precision Promise Industry Working Group, Trovagene will contribute to sub-study design and future study objectives.
TrovaGene, Inc. (TROV)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||4.10 x 6600|
|Ask||4.15 x 3600|
|Day's Range||4.10 - 4.15|
|52wk Range||2.85 - 7.18|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.44|
|Avg Vol (3m)||241,710|
|Dividend & Yield||N/A (N/A)|